Spoken Alpha
Skye Bioscience, Inc.
Skye Bioscience develops nimacimab, a monoclonal antibody that inhibits the CB1 receptor to treat obesity, overweight, and metabolic disorders.
Skye Bioscience, Inc is a Healthcare company operating in Biotechnology with a $9.1M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
6 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SKYE.
$ curl https://api.spokenalpha.com/v1/companies/SKYEFAQ
Spoken Alpha indexes SKYE's earnings call transcripts at https://spokenalpha.com/companies/SKYE. Each call links to attributed speakers and parsed analyst Q&A. Skye Bioscience, Inc.'s own investor relations page is at https://ir.skyebioscience.com/.
Skye Bioscience, Inc. (SKYE) held its most recent earnings call on 2025-11-10, covering fiscal Q3 2025.
Skye Bioscience, Inc. (SKYE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-2.88 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-13 | $-0.27 | $-0.29 | +6.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-0.32 | $-0.32 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-2.95 | $-2.45 | -20.2% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.32 | $-0.32 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.44 | $-0.34 | -29.4% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.28 | $-0.29 | +3.5% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.29 | $-0.28 | -2.2% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.10 | $-0.25 | +60.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-0.20 | $-0.19 | -5.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.18 | $-0.16 | -12.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-21 | $-0.63 | $-0.38 | -65.8% | $163.4K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-3.17 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.00 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-30 | $-0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.01 | — | — | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-31 | $-0.01 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-01 | $-0.01 | — | — | $0 | — | — | EODHD |
Source: EODHD. SKYE reported actuals as published; sparse fields render as —.